A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer

Trial Profile

A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Basal cell cancer; Malignant melanoma; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Blaze Bioscience
  • Most Recent Events

    • 27 Oct 2015 According to a Blaze Bioscience media release, data from this study will be presented at the 2015 2nd Global Advances and Controversies in Skin Cancer (GAC-SC) Conference.
    • 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
    • 27 May 2015 According to a Blaze Bioscience media release, data from this study will be presented at the American Society of Surgical Oncology (ASCO) 2015 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top